Advanced search
Publication Cover
Current Medical Research and Opinion Volume 27, 2011 - Issue 7
Submit an article Journal homepage
468
Views
11
CrossRef citations to date
0
Altmetric
Original Article

Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers

Y.-L. HeNovartis Institutes for Biomedical Research Inc., Cambridge, MA, USACorrespondence[email protected]
,
Y. ZhangNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA
,
D. SerraNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA
,
Y. WangNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA
,
M. Ligueros-SaylanNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA
&
W.P. DoleNovartis Institutes for Biomedical Research Inc., Cambridge, MA, USA
Pages 1453-1463 | Accepted 29 Apr 2011, Published online: 24 May 2011

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Thomas Forst & Peter Bramlage. (2014) Vildagliptin, a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin. Expert Opinion on Pharmacotherapy 15:9, pages 1299-1313.
Read now

Articles from other publishers (10)

GR Sridhar, Kaushik Pandit, Sona Warrier & Ashish Birla. (2023) Sustained-Release Vildagliptin 100 mg in Type 2 Diabetes Mellitus: A Review. Cureus.
Crossref
Antonis A. Manolis, Theodora A. Manolis & Antonis S. Manolis. (2018) Cardiovascular Safety of Antihyperglycemic Agents: “Do Good or Do No Harm”. Drugs 78:15, pages 1567-1592.
Crossref
Pongpan Tanajak, Piangkwan Sa-nguanmoo, Sivaporn Sivasinprasasn, Savitree Thummasorn, Natthaphat Siri-Angkul, Siriporn C Chattipakorn & Nipon Chattipakorn. (2018) Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury. Journal of Endocrinology 236:2, pages 69-84.
Crossref
Sivaporn Sivasinprasasn, Pongpan Tanajak, Wanpitak Pongkan, Wasana Pratchayasakul, Siriporn C. Chattipakorn & Nipon Chattipakorn. (2017) DPP-4 Inhibitor and Estrogen Share Similar Efficacy Against Cardiac Ischemic-Reperfusion Injury in Obese-Insulin Resistant and Estrogen-Deprived Female Rats. Scientific Reports 7:1.
Crossref
Sivaporn SivasinprasasnPiangkwan Sa-nguanmoo, Wanpitak Pongkan, Wasana Pratchayasakul, Siriporn C. Chattipakorn & Nipon Chattipakorn. (2016) Estrogen and DPP4 inhibitor, but not metformin, exert cardioprotection via attenuating cardiac mitochondrial dysfunction in obese insulin-resistant and estrogen-deprived female rats. Menopause 23:8, pages 894-902.
Crossref
Simon Heller, Börje Darpö, Malcolm I. Mitchell, Helle Linnebjerg, Derek J. Leishman, Nitin Mehrotra, Hao Zhu, John Koerner, Mónica L. Fiszman, Suchitra Balakrishnan, Shen Xiao, Thomas G. Todaro, Ingrid Hensley, Brian D. Guth, Eric L. Michelson & Philip Sager. (2015) Considerations for assessing the potential effects of antidiabetes drugs on cardiac ventricular repolarization: A report from the Cardiac Safety Research Consortium. American Heart Journal 170:1, pages 23-35.
Crossref
Gillian M. Keating. (2014) Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus. Drugs 74:5, pages 587-610.
Crossref
Asfandyar Sheikh. (2013) Direct cardiovascular effects of glucagon like peptide-1. Diabetology & Metabolic Syndrome 5:1.
Crossref
Pitchai Balakumar & Sokkalingam A. Dhanaraj. (2013) Cardiovascular pleiotropic actions of DPP-4 inhibitors: A step at the cutting edge in understanding their additional therapeutic potentials. Cellular Signalling 25:9, pages 1799-1803.
Crossref
Bo Ahrén. (2012) Vildagliptin: a DPP-4 inhibitor for the treatment of Type 2 diabetes. Diabetes Management 2:5, pages 453-464.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.